SAN DIEGO–(BUSINESS WIRE)–Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today it has entered into a research collaboration agreement with the

Read the original post:
Inovio Biomedical and NIH Vaccine Research Center Sign Research Collaboration Agreement to Develop Universal Influenza Vaccines

Related posts:

1. Neugenesis and PATH Sign Collaboration Agreement to Develop an Influenza Vaccine Production System BURLINGAME, Calif.--(BUSINESS WIRE)--Neugenesis Corporation today announced a collaboration with PATH...
2. Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses in Animal Studies SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader...
3. Inovio, NIH to develop swine flu vaccine – Reuters Inovio, NIH to develop swine flu vaccine Reuters Aug...
4. Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in...
5. Inovio, NIH collaborating on flu vaccines – Bizjournals.com Inovio, NIH collaborating on flu vaccines Bizjournals.com Under the...

Related posts brought to you by Yet Another Related Posts Plugin.

Tags | biomedical, diego, dna, mexico, newsvine, obama, second-round, swine flu, swine flu mask, the-health, very-big, yahoo